The two biotech stocks highlighted in today’s article both made their public market debuts in 2018 – and both have performed very well for investors who have held them from the beginning. More importantly, for investors who missed out on this outperformance, the author believes there’s good reason to expect further outperformance from both stocks going forward, making them both potential buys right now. For more, CLICK HERE.
Amid a third-quarter earnings season that has been a mixed bag of beats and misses for drug/biotech companies, today’s article highlights five drug/biotech stocks that appear poised to deliver a positive earnings surprise in their upcoming quarterly results, as they all have a combination that has been shown to increase the odds of an earnings beat by as much as 70%. For these five drug/biotech stocks, CLICK HERE.
An intranasal vaccine, an mRNA vaccine, and a T-cell activation vaccine: the three biotech companies discussed in today’s article are approaching the virus that causes COVID-19 from different directions, but they have in common ‘Buy’ ratings from one investment banking firm that sees significant upside potential for each, as well as overall bullish sentiment from the broader analyst community. For more on these three COVID-19 vaccine stocks, CLICK HERE.
When it comes to the biotech stock that’s the focus of today’s article, which plummeted in mid-October when the company abruptly pulled the plug on a critical Phase 2 trial due to safety concerns with the drug being studied, the author says the following: “We view the drop in the shares as an overreaction, and it has created an excellent buying opportunity. At current levels the stock has minimum downside risk, while its upside is unlikely to be affected by the disappointment.” For the stock in question that could be a good “bad news buy”, CLICK HERE.
October has seen the FDA approve the first drug for COVID-19 (remdesivir), the first treatment for Ebola virus (Regeneron Pharmaceuticals’ Inmazeb), and the first drug regimen approved for mesothelioma in 16 years, among other approvals. Now, today’s article takes a look at the biotech companies awaiting FDA rulings in November. For more, CLICK HERE.
When it comes to the seven “unhealthy” biotech stocks that are the focus of today’s article, the author advises the following: “While these aren’t terrible stocks, they’re stocks best exited before a correction hits or their momentum slows further.” For these seven biotech stocks to consider selling “before they sicken your portfolio”, CLICK HERE.
Amid setbacks for various potential COVID-19 vaccines and treatments, election risk, strengthening M&A activity, and more, what’s the outlook for healthcare and biotech in the final months of 2020? In regards to biotech, the author of today’s article believes that the “5-month sideways consolidation is setting up the stage for a strong rally higher once the market breaks out. And that can happen soon.” For more – including a list of promising biotechs and other healthcare companies – CLICK HERE.
In March, two small biotechs partnered to develop a vaccine for COVID-19 using a mechanism called RNA interference (RNAi) – and early data for the drug they ended up developing was positive. So where do things stand now with their vaccine effort, what are the prospects for the future, and which – if either – of the two firms may be a good investment right now? CLICK HERE.
The biotech stock highlighted in today’s article is already up 173% so far this year, and now the author advises that “a historically bullish signal flashing on the charts could indicate even more upside for [the stock] in the coming weeks.” For the stock in question, and how traders looking to speculate on its next move higher may want to go about doing so, CLICK HERE.
The biotech company highlighted in today’s article, specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer, is one that the author has on his list of high-return-potential candidates. Before taking a position in the stock, however, he cautions that investors need to be aware of one issue of concern that could have important consequences for the stock in the short and medium term. For more, CLICK HERE.